Cargando…

Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa

Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three mea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampogna, Francesca, Campana, Irene, Fania, Luca, Mastroeni, Simona, Fusari, Roberta, Ciccone, Davide, Pallotta, Sabatino, Abeni, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397122/
https://www.ncbi.nlm.nih.gov/pubmed/34441944
http://dx.doi.org/10.3390/jcm10163648
_version_ 1783744543577866240
author Sampogna, Francesca
Campana, Irene
Fania, Luca
Mastroeni, Simona
Fusari, Roberta
Ciccone, Davide
Pallotta, Sabatino
Abeni, Damiano
author_facet Sampogna, Francesca
Campana, Irene
Fania, Luca
Mastroeni, Simona
Fusari, Roberta
Ciccone, Davide
Pallotta, Sabatino
Abeni, Damiano
author_sort Sampogna, Francesca
collection PubMed
description Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three measures: (a) question 1 (“my skin hurts”) of the Skindex-17; (b) Bodily Pain (BP) scale of the SF-36; and (c) Visual Analog Scale (VAS). Clinical severity of HS was assessed by the Hurley staging, the Sartorius HS Score, and the International HS Severity Score System. Results. The study population included 341 HS patients with complete data for the VAS pain, 316 for question 1 of the Skindex-17, and 294 for BP. Clinical severity was positively associated with pain. This result was observed for all three severity scores and all three pain evaluation methods. In addition, the number of fistulae, abscesses, and nodules were significantly associated with the three severity measures of pain, while the association with scars was not observed for question 1 of the Skindex-17 and BP. Conclusions. Pain may be a good proxy of clinical severity and efficacy of a treatment in HS and therefore a crucial hallmark of patients’ health status.
format Online
Article
Text
id pubmed-8397122
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83971222021-08-28 Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa Sampogna, Francesca Campana, Irene Fania, Luca Mastroeni, Simona Fusari, Roberta Ciccone, Davide Pallotta, Sabatino Abeni, Damiano J Clin Med Article Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three measures: (a) question 1 (“my skin hurts”) of the Skindex-17; (b) Bodily Pain (BP) scale of the SF-36; and (c) Visual Analog Scale (VAS). Clinical severity of HS was assessed by the Hurley staging, the Sartorius HS Score, and the International HS Severity Score System. Results. The study population included 341 HS patients with complete data for the VAS pain, 316 for question 1 of the Skindex-17, and 294 for BP. Clinical severity was positively associated with pain. This result was observed for all three severity scores and all three pain evaluation methods. In addition, the number of fistulae, abscesses, and nodules were significantly associated with the three severity measures of pain, while the association with scars was not observed for question 1 of the Skindex-17 and BP. Conclusions. Pain may be a good proxy of clinical severity and efficacy of a treatment in HS and therefore a crucial hallmark of patients’ health status. MDPI 2021-08-18 /pmc/articles/PMC8397122/ /pubmed/34441944 http://dx.doi.org/10.3390/jcm10163648 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sampogna, Francesca
Campana, Irene
Fania, Luca
Mastroeni, Simona
Fusari, Roberta
Ciccone, Davide
Pallotta, Sabatino
Abeni, Damiano
Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
title Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
title_full Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
title_fullStr Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
title_full_unstemmed Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
title_short Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
title_sort pain as defining feature of health status and prominent therapeutic target in patients with hidradenitis suppurativa
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397122/
https://www.ncbi.nlm.nih.gov/pubmed/34441944
http://dx.doi.org/10.3390/jcm10163648
work_keys_str_mv AT sampognafrancesca painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT campanairene painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT fanialuca painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT mastroenisimona painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT fusariroberta painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT cicconedavide painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT pallottasabatino painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa
AT abenidamiano painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa